Copyright (c) 2006 Cancer Consultants. All rights reserved.Professional Cancer News from all disease categories.http://rss.cancerconsultants.com/ProFeed.aspx60http://professional.cancerconsultants.com/news.aspx?id=44824http://professional.cancerconsultants.com/news.aspx?id=44824Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that dutasteride, a 5-alpha-reductase inhibitor that inhibits conversion of testosterone into dihydrotestosterone, was effective in reducing the risk of biopsy-proven prostate cancer in men with an elevated prostate specific antigen (PSA) with negative prostate biopsies. The details of this study were published in the April 1, 2010 issue of the New England Journal of Medicine.1 Preliminary results of this study were reported reported at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24. jmaxon@onco-ed.com (jenny maxon)Mon, 05 Apr 2010 09:02:01 GMThttp://professional.cancerconsultants.com/news.aspx?id=44823http://professional.cancerconsultants.com/news.aspx?id=44823Researchers from Sweden have reported a 19% increased risk of breast cancer in women taking multivitamins. The details of this study were published early online on March 24, 2010 in the American Journal or Clinical Nutrition.1 However, other large studies have not found such an association.jmaxon@onco-ed.com (jenny maxon)Mon, 05 Apr 2010 08:55:08 GMThttp://professional.cancerconsultants.com/news.aspx?id=44820http://professional.cancerconsultants.com/news.aspx?id=44820Researchers from the University of Pittsburgh have reported that single-agent Mylotarg® (gemtuzumab ozogamicin) results in a complete remission (CR) rate of 30% in patients 70 years or older with newly diagnosed acute myeloid leukemia (AML). The details of this study were published early online in Cancer on March 30, 2010.jmaxon@onco-ed.com (jenny maxon)Fri, 02 Apr 2010 11:59:37 GMThttp://professional.cancerconsultants.com/news.aspx?id=44819http://professional.cancerconsultants.com/news.aspx?id=44819Researchers from the Dana-Farber Cancer Center have reported that six cycles of ABVD is effective and safe for patients with “limited-stage, nonbulky HL [Hodgkin’s lymphoma] and would spare young patients radiation toxicity.” The details of this study were published in the March, 20 2010 issue of the Journal of Clinical Oncology.jmaxon@onco-ed.com (jenny maxon)Fri, 02 Apr 2010 11:45:24 GMThttp://professional.cancerconsultants.com/news.aspx?id=44815http://professional.cancerconsultants.com/news.aspx?id=44815Researchers from the National Cancer Institute have reported that the combination of Avastin® (bevacizumab), Thalomid® (thalidomide), Taxotere® (docetaxel), and prednisone is a highly effective with manageable toxicities in men with hormone refractory prostate cancer (HRPC). The details of this study were published early online on March 22, 2010 in the Journal of Clinical Oncology.jmaxon@onco-ed.com (jenny maxon)Thu, 01 Apr 2010 10:26:52 GMThttp://professional.cancerconsultants.com/news.aspx?id=44814http://professional.cancerconsultants.com/news.aspx?id=44814Researchers from Italy have reported that adjuvant FOLFOX-4 (leucovorin, 5-FU, and oxaliplatin) for eight cycles and concomitant radiotherapy “is feasible and effective for the treatment of patients with high-risk gastric cancer.” The details of this study were published in the March 2010 issue of the Archives of Surgery.jmaxon@onco-ed.com (jenny maxon)Thu, 01 Apr 2010 10:18:25 GMThttp://professional.cancerconsultants.com/news.aspx?id=44811http://professional.cancerconsultants.com/news.aspx?id=44811Researchers affiliated with the Vitamins and Lifestyle (VITAL) Study have reported that women receiving estrogen and progesterone hormone replacement therapy (HRT) for 10 years or more have an approximate 50% increased risk of developing lung cancer. The details of this study were published in the March 20, 2010 issue of the Journal of Clinical Oncology.jmaxon@onco-ed.com (jenny maxon)Wed, 31 Mar 2010 11:00:03 GMThttp://professional.cancerconsultants.com/news.aspx?id=44810http://professional.cancerconsultants.com/news.aspx?id=44810Researchers from Europe affiliated with the Herceptin® (trastuzumab), Cytoxan® (cyclophosphamide), and Ellence® (epirubicin) (HERCULES) trial have reported that this regimen is effective and tolerable for women with newly diagnosed HER2-positive (HER2+) metastatic breast cancer. The details of this study were published in the March 20, 2010 issue of the Journal of Clinical Oncology.jmaxon@onco-ed.com (jenny maxon)Wed, 31 Mar 2010 10:48:09 GMThttp://professional.cancerconsultants.com/news.aspx?id=44805http://professional.cancerconsultants.com/news.aspx?id=44805Researchers from the UK have reported that a regimen of 5-FU, cisplatin, and streptozocin is an effective and tolerable regimen for treatment of newly diagnosed patients with neuroendocrine tumors. The details of this Phase II study were published early online on March 16, 2010 in the British Journal of Cancer.jmaxon@onco-ed.com (jenny maxon)Tue, 30 Mar 2010 09:39:14 GMThttp://professional.cancerconsultants.com/news.aspx?id=44804http://professional.cancerconsultants.com/news.aspx?id=44804Researchers from France and the UK have reported that a dose of as little as 5 Gy of radiation therapy to the heart for the treatment of childhood cancers results in a significant increase in cardiac death later in life. The details of this study were published in the March 10, 2010 issue of the Journal of Clinical Oncology.jmaxon@onco-ed.com (jenny maxon)Tue, 30 Mar 2010 09:29:46 GMT